PDCD1 and neoplasm: Facts also proved this point of view, a clinical trial of TIM-3 antibody (sabatolimab) combined with PD-1 antibody (spartalizumab) showed anti-tumor activity and well tolerated in the treatment of advanced solid tumors (88).